Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

“This is the first of several reports based on the FNIH bone-quality initiative,” he said. “We hope to be publishing soon on bone-mineral density and later on the combination of bone-turnover markers and bone mineral density.”

One of the 10 authors is employed by Merck & Co.; another is employed by Amgen, Inc.

Reference

1. Bauer DC, Black DM, Bouxsein ML, et al. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. Journal of Bone Mineral Research. 2018 Jan 10.  [Epub ahead of print]